Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

2. Cardiovascular System Guidelines

Anticoagulation Guidance

BNSSG DOAC decision aid March 2020

BNSSG Summary of considerations when prescribing a DOAC

Anticoagulant and antiplatelet co–prescribing information

BNSSG Anticoagulation questions and answers July 2013

Changing Anticoagulants v53

NBT NOAC counselling checklist

NICE KTT16 Anticoagulants including DOACs Updated Sep 2016

NOAC Decision aid July 16

UHB Anticoagulants Counselling Jan 13

UKMI Oral Anticoagulants in AF


Anticoagulation Patient Information Leaflets

Anticoagulation in AF

Anticoagulation patient information leaflet 2018

BNSSG Apixaban in AF Leaflet April 13
BNSSG Apixaban in AF Leaflet for printing April 13

BNSSG Dabigatran in AF Leaflet July 12
BNSSG Dabigatran in AF Leaflet for printing July 12

BNSSG Rivaroxaban in AF Leaflet July 12
BNSSG Rivaroxaban in AF Leaflet for printing July 12

Anticoagulation in DVT

Anticoagulation choices leaflet v2 in DVT June 15 –final – for printing (rotated version)
Anticoagulation choices v2 in DVT June 15–final unrotated


Antiplatelet Guidance

Antiplatelet Guidelines May 17 BNSSG

Ticagrelor AGWS cardiac network guidelines Sept 12


Statin Guidance

BNSSG Management of Blood Lipid Levels (Statin Guidelines) 2020


Heart Failure Guidance

Primary care heart failure guidelines


Raynaud's Phenomenon

Due to significant disruption with the supply of a number of Nifedipine preparations, see local advice document on alternative options for the management of Raynaud's Phenomenon, available here 

Medical Management of Raynauds Phenomenon in view of Nifedipine supply changes (Nov 19).pdf